3 Hidden-Gem Small-Caps Flying Under Wall Street's Radar

The social sentiment data this week is drowning in SpaceX capex drama and Iran deal theater. Fine. While the crowd fights over those table scraps, let's talk about three companies most people couldn't name in a trivia contest, each with a genuine reason to exist on your watchlist.

$RCUS (Arcus Biosciences, NYSE) is a clinical-stage biotech focused on cancer immunotherapy, specifically combinations targeting adenosine pathway receptors. Market cap sits comfortably below $2B, which means almost zero institutional fanfare. What makes it interesting right now is its partnership with Gilead Sciences, which has made multiple equity investments totaling over $1.7 billion. Gilead does not write checks that size for companies it is planning to ghost. The bear case is simple: biotech is a binary game, clinical trial failures hit hard, and the stock has already had its share of volatile swings. But if any of its combination therapies hit in a readout, the move could be violent in a very good way.

$GERN (Geron Corporation, NASDAQ) has been in development-stage purgatory for so long it almost became a meme. Then it got FDA approval for Rytelo (imetelstat) for myelodysplastic syndromes in mid-2024, making it a legitimate commercial-stage company for the first time in its history. Market cap is still under $1.5B, which is frankly absurd for a company with an approved drug. The reason it stays cheap is that MDS is a niche indication with a modest patient population, and Geron has to prove it can actually sell the drug, not just invent it. Near-term catalysts include quarterly prescription data and any label expansion discussions. A real commercial ramp would force a rerating.

$CARM (Carisma Therapeutics, NASDAQ) is so small and so early-stage that its name sounds like a wellness app. It is actually a macrophage-based cell therapy company working on a completely different approach to solid tumor treatment, one of oncology's hardest problems. Market cap is under $200M, volume is thin, and analyst coverage is basically nonexistent. That is exactly the hidden-gem profile this category is built for. The catalyst to watch is clinical data from its CAR-M program. If that data looks even vaguely interesting, the stock moves fast on very little liquidity.

None of these are the kind of names Jamie Dimon is worried about when he talks about record margin debt. They are exactly the kind of asymmetric, under-the-radar setups that get ignored when everyone is busy arguing about whether SpaceX's $18 billion capex is genius or insanity. Spoiler: it might be both.